Commonwealth Numbered Regulations

1984 No. 169 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 4

SCHEDULE 4
Regulation 6
AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH
(PHARMACEUTICAL BENEFITS) REGULATIONS
1. After item 6 insert the following item:
   "6A Amiodarone Hydrochloride       With the written authority of the

Secretary-
For the continuing treatment of severe
refractory cardiac arrhythmias where
treatment with amiodarone hydrochloride
was initiated in a hospital".
2. Omit item 21, substitute the following item:

"21 Calcium Carbonate, B.P.,
with Calcium Lactate-Gluconate        With the written authority of the

                                      Secretary-   Hypocalcaemia

Osteoporosis
Proven malabsorption".
3. Omit item 28, substitute the following item:
   "28 Carindacillin Sodium           With the written authority of the

Secretary-
Urinary tract infections where positive
bacteriological evidence confirms that
carindacillin or carbenicillin is the
most appropriate therapeutic agent".
4. Omit items 43 and 43A, substitute the following item:
   "43 Cimetidine                     With the written authority of the

Secretary-
Duodenal ulcer, confirmed by radiology,
endoscopy or surgery
Gastric ulcer, confirmed by radiology,
endoscopy or surgery
Zollinger-Ellison syndrome, proven by
investigation".
5. Omit item 47, substitute the following item:

"47 Codeine Phosphate, B.P., with Aspirin, B.P., Tablets,
30 mg-325 mg                          With the written authority of the

                                      Secretary-   Disabling pain associated

with proven malignant neoplasia".
6. After item 50 insert the following item:

"50A (1) Cyclophosphamide, B.
P.       (2)  Cyclophosphamide

Tablets, B.P.                         With the written authority of the

                                      Secretary-   Anaemia, autoimmune,

                                      haemolytic   Arthritis, rheumatoid with

vasculitis orvisceral complications
Continuing cyclophosphamide therapy
initiated in a hospital
Dermatomyositis
Granulomatosis, Wegener's
Hepatitis, active, chronic
Lupus erythematosus, systemic
Malignant disease including leukaemia
Nephritis
Nephrotic syndrome
Polyarteritis nodosa
Scleroderma
Thrombocytopenic purpura".
7. Omit item 54, substitute the following item:
   "54 'DE-LACT  INFANT'              Acute gastro-enteritis complicated by

lactose intolerance in infants who have
not attained the age of twelve (12)
months
Proven lactose intolerance in infants
who have not attained the age of twelve

(12) months".
8. Omit item 58, substitute the following items:

"58 (1) Dextromoramide Tablets, B.P.

(2) Dextromoramide
    Tartrate, B.P.                    Disabling pain associated with proven

malignant neoplasia
   "58A Diflunisal Tablets, B.P.      Chronic osteoarthritis

Chronic rheumatoid arthritis".
9. Omit item 65. 10. Omit item 86, substitute the following items:

"86 Hydrocortisone Acetate, B.
P., Rectal Foam                       Proctitis

Ulcerative colitis

"86A Hydrocortisone Acetate
Injection, B.P.                       Alopecia areata

For local intra-articular or
peri-articular infiltration
Granulomata, dermal
Keloid
Lichen planus hypertrophic
Lichen simplex chronicus
Lupus erythematosus, chronic discoid". 11. Omit item 96, substitute the
following item:
   "96 Lincomycin Injection, B.P.     Gram-positive coccal infections where

these cannot be safely and effectively
treated with penicillin or a derivative
of penicillin". 12. Omit item 102, substitute the following item:

"102 Medroxyprogesterone
Acetate, B.P., Tablets, 10 mg         Breast cancer

Dysfunctional uterine bleeding
Endometrial cancer
Endometriosis
Precocious puberty
Renal cell cancer
Turner's syndrome". 13. Omit item 114, substitute the following item:

"114 Metoclopramide
Hydrochloride, B.P.                   With the written authority of the

                                      Secretary-   Malignant neoplasia (late

stage)
Gastric stasis due to gastric surgery,
diabetic gastroparesis or scleroderma". 14. Omit items 130 and 131, substitute
the following item:

"130 (1) Oxycodone Hydrochloride
      (2)  Oxycodone Pectinate        Disabling pain associated with proven

malignant neoplasia". 15. Omit item 151, substitute the following item:

"151 Prednisolone Acetate
Injection                             For local intra-articular or

peri-articular infiltration". 16. Omit items 161A, 162, 163 and 164,
substitute the following items:
   "161A Ranitidine Hydrochloride     With the written authority of the

Secretary-
Duodenal ulcer, confirmed by radiology,
endoscopy or surgery
Gastric ulcer, confirmed by radiology,
endoscopy or surgery
Zollinger-Ellison syndrome, proven by
investigation
   "161B Rifampicin, B.P.             With the written authority of the

Secretary-
Leprosy in adults
Prophylaxis of meningococcal disease
in close contacts and carriers

"162 Silver Sulphadiazine with Chlorhexidine Gluconate
Cream                                 With the written authority of the

                                      Secretary-   Treatment, in a hospital,

of burns

"163 Sodium Cromoglycate, B.P.,
Eye Drops                             With the written authority of the

                                      Secretary-   Vernal
kerato-conjunctivitis

"164 Sodium Cromoglycate, B.P.,
Nebuliser Solution                    Use in a power-operated nebuliser for

prophylaxis of asthma in persons who are
unable to use the capsule for oral
inhalation". 17. Omit items 166 and 167, substitute the following item:

"166 (1) Sodium Valproate, B.
P.       (2)  Sodium Valproate
Elixir, B.P.

(3) Sodium Valproate
Tablets, B.P.                         Epilepsy".
18. Omit item 184, substitute the following item:

"184 Triamcinolone Acetonide,
B.P., Injection                       Alopecia areata

For local intra-articular or
peri-articular infiltration
Granulomata, dermal
Keloid
Lichen planus hypertrophic
Lichen simplex chronicus
Lupus erythematosus, chronic discoid
Necrobiosis lipoidica
Psoriasis".